Hinge Health Raises Full-Year 2026 Revenue Guidance by $20M, Announces Investor Day
HNGE has more than doubled off its 52-week low of $30.08.
Summary
Hinge Health raised its full-year 2026 revenue guidance and announced its first Investor Day, signaling continued strong performance and management's positive outlook.
Key Events · Earnings and Guidance · HNGE
-
Raised Full-Year 2026 Revenue Guidance
New range of $818 million to $824 million, up $20 million at the midpoint from prior guidance, representing 40% year-over-year growth.
-
Strong Q2 2026 Outlook
Projects Q2 revenue between $200 million and $202 million (45% YoY growth) and non-GAAP operating income of $50 million to $52 million (25% margin).
-
Increased Operating Margin Expectation
Full-year 2026 non-GAAP operating margin now expected at 27% at the midpoint.
-
Inaugural Investor Day Announced
Company to host its first Investor Day on June 10, 2026, to discuss strategy and future opportunities.
Analysis · HNGE · Technology
Hinge Health has increased its full-year 2026 revenue guidance by $20 million at the midpoint, now expecting $818 million to $824 million, reflecting 40% year-over-year growth. This positive revision, coupled with strong Q2 2026 projections and a 27% non-GAAP operating margin, indicates sustained business momentum and management confidence. The company is also hosting its first Investor Day, which will provide further strategic insights.
At the time of this filing, HNGE was trading at $64.01 on NYSE in the Technology sector, with a market capitalization of approximately $4.9B. The 52-week trading range was $30.08 to $66.55. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.